
LegalJul 27, 2026, 04:38 PM
SELLAS Life Sciences Arbitration Claims Dismissed; $1M Payment
AI Summary
SELLAS Life Sciences Group, Inc. announced that its claims in a binding arbitration against 3D Medicines, Inc. were dismissed. As a result, the company is required to pay 3D Medicines approximately $1.0 million for legal fees and costs. Despite the arbitration outcome, $191.5 million in potential future milestone payments, including $13.0 million previously in dispute, remain under the exclusive license agreement for galinpepimut-S in Greater China. Additionally, the company reported an estimated unaudited cash and cash equivalents position of $138.3 million as of June 30, 2026.
Key Highlights
- SELLAS Life Sciences' claims in binding arbitration against 3D Medicines were dismissed.
- The company is required to pay 3D Medicines approximately $1.0 million in legal fees and costs.
- 3D Medicines will continue to progress galinpepimut-S (GPS) development in Greater China.
- Potential future milestone payments of $191.5 million remain under the exclusive license agreement.
- This includes $13.0 million in milestone payments that were previously in dispute.
- Estimated unaudited cash and cash equivalents were $138.3 million as of June 30, 2026.
Price Impact
More from SLS